Phagenesis develops invaluable treatment to transform the lives of patients who have difficulty swallowing
Dysphagia is the term used to describe difficulty in swallowing or inability to swallow safely. It has numerous underlying causes, and extensive data has also found neurogenic dysphagia following stroke, traumatic brain Injury, prolonged mechanical ventilation, critical Illness polyneuropathy, MR, and epilepsy.
The Phagenesis® mission is to transform the lives of people with dysphagia, using revolutionary treatments developed through a commitment to scientific and clinical excellence.
The first product in the portfolio is Phagenyx®, a treatment that addresses the underlying neurological causes of dysphagia. Restoration of the systems and processes for neurological control and coordination of swallowing is the key starting point for swallowing rehabilitation.
The Phagenyx® system is the result of more than 20 years of research and development led by Professor Shaheen Hamdy.
Following convincing clinical data, new guidelines from the German Society of Neurology (DGN) for neurogenic dysphagia recommends the Phagenyx treatment as best practice for tracheotomised patients with dysphagia.
Phagenyx has also recently been shown to provide significant benefits in the treatment of dysphagia in COVID-19 patients, who are at particular risk from the condition.
